Table 1.
Baseline Characteristics of 417 Ultra Low Dose Transdermal estRogen Assessment Participants by Treatment Group
| Estradiol n = 20 | Placebo n = 20 | P* | |
|---|---|---|---|
| Age | 66.8 ± 5.1 | 66.7 ± 4.8 | .96 |
| Years since menopause | 37.0 ± 5.1 | 37.4 ± 4.7 | .57 |
| White race | 92.8 | 91.9 | .45 |
| Body mass index | 28.3 ± 5.3 | 28.0 ± 5.3 | .60 |
| Parity | 3.2 ± 1.7 | 3.3 ± 1.8 | .70 |
| Medical conditions | |||
| Diabetes | 3.4 | 1.0 | .09 |
| Hypertension | 16.4 | 14.8 | .65 |
| Current smoker | 7.7 | 6.2 | .55 |
| Estradiol level in pg/mL [median (interquartile range)] | 4.8 (2.7–8.0) | 4.7 (2.7–8.3) | .62 |
| Weekly or more frequent incontinence | |||
| Any type | 41.3 | 44.0 | .62 |
| Stress | 25.0 | 27.5 | .53 |
| Urge | 26.0 | 25.8 | 1.00 |
| Frequency of incontinence, episodes/wk | |||
| None | 58.6 | 56.5 | .80 |
| 1 | 16.8 | 16.9 | |
| 2–6 | 18.8 | 18.4 | |
| ≥ 7 | 5.8 | 8.2 | |
| Incontinence type, mean episodes/wk | |||
| Any | 1.9 ± 6.9 | 1.7 ± 4.3 | .57 |
| Stress | 1.3 ± 6.0 | 1.1 ± 3.6 | .47 |
| Urge | 0.6 ± 1.8 | 0.7 ± 1.7 | .84 |
SD, standard deviation.
Values are mean ± standard deviation or %, except where otherwise specified.
*
The P values for categorical variables were calculated using generalized Cochran-Mantel-Haenszel tests, stratified by clinic site. The P values for continuous variables are from analysis of variance or rank analysis of variance, adjusted for site.